New Two-Drug combo tested to fight aggressive prostate cancer
NCT ID NCT05617885
Summary
This study is testing whether adding two oral drugs, darolutamide and abemaciclib, to standard hormone therapy is safe and effective for men with high-risk prostate cancer. The first part aims to find the best dose, and the second part would have compared the full combination to standard therapy alone. The trial is for men whose cancer has spread or is at high risk of returning, but it did not move to the second phase after the drug company withdrew support.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.